Interferone pp 234-268 | Cite as

Interferontherapie bei ausgewählten soliden Tumoren

  • P. von Wussow

Zusammenfassung

Während verschiedene Interferon-α-Präparationen bereits einen gesicherten Platz bei der Behandlung von Hämoblastosen haben, konnten sich diese Interferone bisher bei der Behandlung solider Tumoren nicht in ähnlicher Weise durchsetzen. Eine Ausnahme bilden das maligne Karzinoid sowie das Kaposi-Sarkom, bei denen heute eine Wirksamkeit der Interferon-Therapie nachgewiesen ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ishihara K, Hayasaki K, and Hasegawa F (1983) Clinical responses of patients with malignant skin neoplasia to intralesional treatment with three types of interferons (a and ß). In: The clinical Potential of Interferons Ed. R Kono, J Vilcek. pp 245–256, Univ of Tokyo PressGoogle Scholar
  2. 2.
    von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61: 1071–1074CrossRefGoogle Scholar
  3. 3.
    Horoszewicz JS, Kong SS, Iro M, Buffet RF, Karokonsis C, Holyoke E, Job L, Dolen JG, Carter WA (1899–1906) Cancer Treat Rep 62Google Scholar
  4. 4.
    Retsas S, Priestman TJ, Newton KA, Westbury G (1983) Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer 51: 273–276PubMedCrossRefGoogle Scholar
  5. 5.
    Goldberg RM, Ayoob M, Silgals R, Ahlgren JD, Neefe JR (1985) Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma. Cancer Treat Rep 69: 813–816PubMedGoogle Scholar
  6. 6.
    Krown SE, Burk MW, Kirkwood JM, Kerr D, Morton DL, Oettgen HF (1984) Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society Phase IIGoogle Scholar
  7. 7.
    Landthaler M, Geyer C, Papendiek U, Braun-Falco O Alpha 2-Interferon-Therapie des metastasierenden malignen Melanoms. Dtsch Med Wochenschr 112:919–921 (1987), Trial. Cancer Treat Rep 68: 723–726 (1984)Google Scholar
  8. 8.
    Robinson WA, Kirkwood J, Harvey H, Mughal T, McCune C, Muggia F, Hawkins M, Muscato M, Pouillart P, Ernstoff M, Sorell M, Spiegel R (1984) Effective use of recombinant human alpha 2 interferon (IFN alpha 2) in metastatic malignant melanoma (MMM): A comparison of two regimens. Proc Annu Meet Am Soc Clin Oncol 3: 60Google Scholar
  9. 9.
    Hawkins MJ, McCune CS, Speyer JL, Sorell M (1984) Recombinant alpha 2 interferon (IFN-alpha 2) (Sch 30500) in patients with metastatic malignant melanoma (MMM): An ECOG Pilot Study. Proc Annu Meet Am Soc Clin Oncol 3: 51Google Scholar
  10. 10.
    Dorval T, Palangie T, Jouve M, Garcia-Giralt E, Falcoff E, Schwab D, Lerminier M, Pouillart P (1987) Treatment of metastatic malignant melanoma with recombinant interferon alpha-2b. Invest New Drugs 5 (Suppl): 61–63CrossRefGoogle Scholar
  11. 10b.
    10b.Hawkins MJ, Barden EC, Cantell K, Wirtanen GW, Sielaf KM, Ma Brain JA, Fox RW, Smith-Zaremba KM (1982) Intraarterial administration of natural leukocyte interferon in advanced tumor patients. UCLA Symp Molec Cell Biol 25: 407–420Google Scholar
  12. 11.
    Coates A, Railings M, Hersey P, Swanson C (1986) Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res 6: 1–4PubMedCrossRefGoogle Scholar
  13. 12a.
    12a.Creagan ET, Ahmann DL, Green SJ, Long HJ, Rubin J, Schutt AJ, Dziewanowski ZE (1984) Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 54: 2844–2849PubMedCrossRefGoogle Scholar
  14. 12b.
    12b.Creagan ET, Ahmann DL, Frytak S, Long HJ, Cang MN, Itri LM (1986) Phase II of recombinant leukocyte A interferon in disseminated malignant melanoma: Results in 96 patients. Cancer Treat Rep 70: 619–624PubMedGoogle Scholar
  15. 12c.
    Creagan E, Ahmann D (1985) Phase II study of recombinant leukocate A interferon ( IFN-rA) plus Cimetidine in disseminated malignant melanoma. J Clin Oncol 3: 977–981Google Scholar
  16. 12d.
    Creagan ET, Ahmann DL, Gree SJ, Long HJ, Frytak S, Itri LM (1985) Recombinant leukocyte A interferon (IFN-alpha A) plus Cimetidine in disseminated malignant melanoma ( DMM ). Proc Am Soc Clin Oncol 4: 126Google Scholar
  17. 13.
    Hersey P, Hasic E, MacDonald M, Edwards A, Spurling A, Coates AS, Milton GW, McCarthy WH (1985) Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumor growth and immune responses in patient with metastatic melanoma. Br J Cancer 51: 815–826PubMedCrossRefGoogle Scholar
  18. 14.
    Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ (1986) Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiol 172: 275–282CrossRefGoogle Scholar
  19. 15.
    Dorval T, Palangie T, Jouve M, Garcia-Giralt E, Israel L, Falcoff E, Schwab D, Puillart P (1986) Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer 58: 215–218PubMedGoogle Scholar
  20. 16.
    Elsasser-Beile U, Drees N, Neumann HA, Schopf E (1987) Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma. J Cancer Res Clin Oncol 113: 273–278PubMedCrossRefGoogle Scholar
  21. 17.
    Legha SS, Papadopoulos NEJ, Plager C, Ring S, Chawla SP, Evans LM, Benjamin RS (1987) Clinical evaluation of recombinant interferon alpha-2a ( Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5: 1240–1246Google Scholar
  22. 18.
    Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R, Rudnick SA (1985) Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 103: 32–36PubMedGoogle Scholar
  23. 19.
    Pouillart P, Bietandeau B, Doval T, et al (1984) Clinical phase II study of recombinant DNA interferon in patients with metastatic malignant melanoma. Antiviral Res 1(3): 92 abstract D 19Google Scholar
  24. 20.
    Flodgren P, Borgstrom S, Jonsson PE, Lindstrom C, Sjogren HO (1983) Metastatic malignant melanoma: Regression induced by combined treatment with interferon (HuIFN- alpha (Le)) and Cimetidine. Int J Cancer 32: 657–665Google Scholar
  25. 21.
    Hill NO, et al (1983) IFN- and Cimetidine combination in malignant melanoma. Kishida T (ed) Interferons. Kyoto, pp 227–238Google Scholar
  26. 22.
    Steiner A, Wolff K, Pehamberger H (1986) Recombinant leukocyte A Interferon and Cimetidine treatment in disseminated melanoma. Eur J Cancer Clin Oncol 22: 1407–1411PubMedCrossRefGoogle Scholar
  27. 22a.
    Mughal TI, Robinson WA, Thomas MR, Garvin PR, Etringer M (1984) Evaluation of rlFN-cib and Cimetidine in metastatic maligment melanoma restistant to rIFN-a2b alone. Clin. Res. 32, 59AGoogle Scholar
  28. 23.
    Ernsthoff MS, Davis CA, Kirkwood JM et al (1985) Cimetidin plus Interferon alpha 2 does not remit metastatic melanoma which has failed IFN alone. Proc Am Met Ann Soc Clin One 4: 62Google Scholar
  29. 24.
    Lipton A, Harvey HA, Simmonds MA, White DS, Sorell M, Grimm M (1984) Lack of enhanced activity of systemic interferon by Cimetidine in malignant melanoma. Proc Annu Meet Am Soc Clin Oncol 3: 56Google Scholar
  30. 25.
    Slater DE, Krown SE, Pinsky CM, Livingston PO, Oettgen HF (1984) Human leukocyte (alpha) interferon (Hu IFN-alpha ( Le) and Cimetidine in malignant melanoma. Proc Annu Meet Am Soc Clin Oncol 3: 54Google Scholar
  31. 26.
    Creagan ET, Ahmann DL, Frytak S, Long HJ, Itri LM (1986) Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer 58: 2576–2578Google Scholar
  32. 27.
    Ito Y, Jinbo K, Miura S, Maeda K (1984) Local application of interferon-beta to skin lesions of malignant melanoma and malignant lymphoma: Clinical and histopathological analysis. Gan To Kagaku Ryoho Cancer and Chemotherapy 11: 1263–1268Google Scholar
  33. 28.
    Lechner W (1987) Therapie des malignen Melanoms mit natürlichen ß-IFN. Internationale Erfahrungen mit natürlichen ß-IFN. 2. Laupheimer Symposium 8 /86. pp 52Google Scholar
  34. 29.
    Sarna GP, Figlin RA, Pertcheck M (1987) Phase II study of Betaserom (BSER17-interferon) as treatment of advanced malignant melanoma. J Biol Response Mod 6: 375–378PubMedGoogle Scholar
  35. 30.
    Ernstoff MS, Trautman T, Davis CA, Reich SD, Witman P, Baiser J, Rudnik S, Kirkwood JM (1987) A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 5: 1804–1810PubMedGoogle Scholar
  36. 31.
    Haase KD, Lange OF, Scheef W (1987) Interferon-gamma treatment of metastasized malignant melanoma. Anticancer Res 7: 335–336PubMedGoogle Scholar
  37. 32.
    Creagan ET, Ahmann DL, Long HJ, Frytak S, Sherwin SA, Chang MN (1987) Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer Treat Rep 71: 843–844PubMedGoogle Scholar
  38. 33.
    Creagan ET, Loprinzi CL, Ahmann DL, Schmid DJ: Phase II trial of the combination of r leukocyte A interferon and r hu IFN- in patients with metastatic malignant melanoma. CancerGoogle Scholar
  39. 34.
    Hill GJ, Kremmtz ET, Hill HZ (1984) Dimethyl-triazan-imidazole carboxamide and combination therapy for melanoma IV late results after complete response to chemotherapy. Cancer 53: 1299–1305PubMedCrossRefGoogle Scholar
  40. 35.
    Talpaz M, Plager C, Quesada J et al (1986) Difluormethylornithine and leukocyte interferon: A phase I study in cancer patients. Eur J Clin Oncol 22: 685–689Google Scholar

Kaposi-Sarkom

  1. 36.
    Safai B (1987) Pathophysiology and Epidemiology of Epidemic Kaposi-Sarcoma Seminars in Oncol. Vol 14, 2 suppl 3: 7–12Google Scholar
  2. 37.
    Ho DD, Hartmann KL, Rota TR et al (1985) Recombinant human IFN-alpha A suppresses HTLV-III replication in vitro. Lancet 1: 602–604PubMedCrossRefGoogle Scholar
  3. 38.
    Krown S et al (1987) The role of Interferon in the therapy of Epedemic Kaposi-Sarcoma. Seminars Oncol. Vol 14, 2 suppl 3: 27–33Google Scholar
  4. 39.
    Contu L, Sulis E, Ceriuncle D, Carcassi C, laNasa G, Pintus A, Pizus F (1987) The role of alpha-interferon in the therapy of Kaposi Sacoma ( AIDS and classic forms) and cutaneous T cell lymphomas. New Trends Ther Ink Lymph 2: 89Google Scholar
  5. 40.
    Krown SE, Real FX (1983) Preliminary observations in the effects of recombinant leukocyte-A-IFN in homosexual men with Kaposi-Sarkoma. New Engl J Med 308, 1071–1076PubMedCrossRefGoogle Scholar
  6. 41.
    Groopman JE, Gotlieb MS (1984) Recombinant 2-IFN-Therapy for Kaposi-Sarcoma associated with the AIDS. Ann Intern Med 100, 671–676PubMedGoogle Scholar
  7. 42.
    Gelmann EP, Preble OT, Steis R, et al (1985) Human lymphoblastoid interferon of Kaposi Sarkoma in the acquired immune deficiency syndrom. Clin. Response and prognostic parameters. Ann J Med 78: 737–741Google Scholar
  8. 43.
    Volberding P, et al (1984) Therapy of Kaposi Sarcoma with interferon. In „AIDS The epidemic of Kaposi Sarcoma with interferon. Eds: Friedman, Laubenstein, p. 63–67Google Scholar
  9. 44.
    Krown SE, Real FX (1986) Treatment with rIFN-a and analysis of prognostic factors. Cancer 57: 1662–1665PubMedCrossRefGoogle Scholar
  10. 45.
    Vadhan-Rj S, Wong G, Guecco C et al (1986) Immunological variables as predictors of prognosis in patients with Kaposi Sarcoma and the acquired immunodeficiency syndrome. Cancer Res 46: 417–425Google Scholar
  11. 46.
    Harwood AR, Osoba D, Hofstader SL, Goldstein MB, Cardella CJ, Holecek MJ, Kemnitz R, Giammarco RA (1979) Kaposi Sarcoma in recipiants of renal transplants. Am J Med 67: 759–765PubMedCrossRefGoogle Scholar
  12. 47.
    Kramer P, Bigmen AB, Tenkate FWJ, Jeekel J, Weimar W (1984) Lancet i:989–991Google Scholar
  13. 48.
    White CW, Sandheimer HM, Crouch EC, Wilson H, Fou LL: Therapy of pulmonary hemangiomatosis with recombinant interferon-alpha 2a. New Engl Med (in press)Google Scholar
  14. 49.
    Ganser A, Brucher W, Brodt HR et al (1986) Treatment of AIDS-Related Kaposi-Sarcoma with recombinant gamma interferon. Onkologie 9: 163–166PubMedCrossRefGoogle Scholar
  15. 50.
    Odajnyk C, Laubenstein L (1985) Therapeutic trial of human gamma interferon in patients with epidemic Kaposi Sarcoma. Proc of ASCO 4:C-237Google Scholar

Malignes Karzinoid

  1. 51.
    Moertel GG, Saur WF, Dockerty MB et al (1961) Life history of the carcinoid tumor of the small intestine. Cancer 14: 901–912PubMedCrossRefGoogle Scholar
  2. 52.
    Oberg K, Grimelius L, Landquist G et al (1981) Update on pancreatic polypeptide as a specific marker for endocrine tumors of the pancreas and the GUT. Acta Med Scand 210: 145–152PubMedCrossRefGoogle Scholar
  3. 53.
    Martensen H, Nobin A, Bengmark S, Linderquist A, Owman T, Sander A (1984) Embolization of the liver in the management of metastatic tumors. J Surg Oncol 27: 152–158CrossRefGoogle Scholar
  4. 54.
    Kools LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahne RG (1986) Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Eng J Med 315: 663–666CrossRefGoogle Scholar
  5. 55.
    Oberg K, Fuña K, Alm G (1983) Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and the carcinoid syndrome. N Engl J Med 309: 129 ’ 133PubMedCrossRefGoogle Scholar
  6. 56.
    Oberg K, Nordheim I, Lind E, Alm G, Lundquist G, Wide L, Jonsdottir B, Magnusson A, and Wilander E: Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.Google Scholar
  7. 57.
    Oberg K, Erikson B, Narheim I (1988) Interferon-treatment of neuro-endocrine tumors of pankreas and gut. Dev Med Virol 4: 195 - 212Google Scholar
  8. 58.
    Doberaner C, Niederle N, Kloke O, Merschel E, Schmidt CG (1987) Zur Behandlung des metastasierenden Karzinoids von ileum und caecum mit rekombinantem Interferonalpha 2b. Onkologie 10, 340 - 344CrossRefGoogle Scholar
  9. 59.
    Kods LK (1986) Metastatic carcinoid tumors and the carcinoid syndrome: a selective review of chemotherapy and hormonal therapy. Am J Med 81: 49 - 55Google Scholar

Hepatozelluläres Karzinom

  1. 60.
    Dunk AA, Ikeda T, Pignatelli M, Thoma HC (1986) Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 2 (3): 419 ’ 429Google Scholar
  2. 61.
    Sachs E, Di bisceglie AM, Dusheiko GM, Song E, Lyons SF, Schomb BD, Kew MC (1985) Treatment of hepatocellular carcinoma with recombinant leukocyte interferon: a pilot study. Br J Cancer 52 (1): 105 – 109PubMedCrossRefGoogle Scholar
  3. 62.
    Nair PV, Tong MJ, Kempf R, Co R, Lee SD, Venturi CL (1985) Clinical serologic and immunologic effects of human leukocate interferon in Hbs-Ag-positive primary hepatocellular carcinoma. Cancer 56 (5): 1018 – 1022PubMedCrossRefGoogle Scholar
  4. 63.
    Okai T, Kato Y, Unoura M, Tanaka M, Kobyashi K, and Hahari N (1983) Antitumor effect of human fibroblast interferon (IFN-ß) on patients with hepatocellular carcinoma (HCC) In „Interferons“ ed. Kshida T p. 415 – 419 Japan Convention Serv; OsakaGoogle Scholar
  5. 64.
    Farbes A, Johnson PJ and William R (1985) Recombinant human interferon-gamma in primary hepatocellular carcinoma. J Res Soc Med 78 (10): 826 - 829Google Scholar
  6. 65.
    Mazzanti R, Pinzani M, Zignego L, Romanelli R, Gentilini P (1986) Recombinant human gamma-interferon in the treatment of hepatocellular carcinoma; Preliminary results of a pilot study. Dig Dis Sei New Series 31 (suppl): 131 – 139Google Scholar
  7. 66.
    Creagan ET, Long HJ, Frytak S, Moertek CG (1988) Recombinant leukocyte A interferon with doxorubin. A phase I-study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer 61 (1), 19 – 22PubMedCrossRefGoogle Scholar

Magen und Pankreas-Ca.

  1. 67.
    Strander H: Interferon treatment of human neoplasia, in „Advances in Cancer Research“ V. 46. S. 170Google Scholar
  2. 68.
    Reh JK, Wooley PV, Reich SD, Coal-Goldsmith S, Neefe JR (1986) Phase II evaluation of recombinant interferon gamma in advanced pancreatic and gastric adenocarcinoma. Proc Am Soc Clin One 5: 85Google Scholar

Kolonkarzinom

  1. 69.
    Waller S, Lyver A, Goldman M, Wiernik PH (1988) Therapy with 5-Fluoruracil and rIFN-a 2a in refrectory GI malignancies. Proc Am Soc Clin One 89, abstract 384Google Scholar
  2. 70.
    Neefe JR, Silgals R, Ayoob M, Schein PS (1984) Minimal activity of recombinant clone a interferon in metastatic colon cancer. J Biol Resp Mod 3 (4): 366–370Google Scholar
  3. 71.
    Niederle N, Kurschel E, Schmidt, CG: Biologischer Effekt von rekombinierten Leukozyten-alpha 2 Interferon bei metastasierten Kolorektalen Karzinomen. Dtsch Med Wochenschr 109 (20), 779–82Google Scholar
  4. 72.
    Clark Ol, Slevin ML, Reznek RH et al (1987) Two randomized Phase II trails of intermittent intravenous versus subcutnenous alpha-2 interferon alone (trial 1) and in combination with 5-Fluoruracil (trial 2) in advanced colorectal Cancer. Int J Color Dis 2 (1), 26–29CrossRefGoogle Scholar
  5. 73.
    Lundell G, Blomgren H, Cedermark B et al (1984) High dose rDNA human alpha 2 interferon therapy in patients with advanced colorectal adenocarcinoma: a phase II study. Radio Ther Oncol 1 (4): 325–332CrossRefGoogle Scholar
  6. 74.
    Silgals RM, Ahlgren JD, Neefe JR et al (1984) a phase II trial of high-dose intravenous interferon alpha 2 in advanced colorectal Cancer. Cancer 54 (10): 2257–2261Google Scholar
  7. 75.
    Eggermont AM, Weimar W, Tank B et al (1986) Clinical and immunological evaluation of 20 patients with leukocyte interferon alpha a. Cancer Immunol. Immunother 21 (1): 81–84CrossRefGoogle Scholar
  8. 76.
    Krown SE, Mintzer D, Cunningham-Rundles S, et al (1987) High dose human lympho- blastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treatment Rep 71 (l): 39–45Google Scholar
  9. 77.
    Flodgreen P, Hugander A, Sjögren HO (1985) Recombinant leukocyte A interferon as single agent therapy or in combination with Cimetidine in patients with advanced colorectal carcinom. Acta Radiologica Oncology 24: 25–24CrossRefGoogle Scholar
  10. 78.
    Figlin RA, Callaghan M, Sarna G (1983) Phase II trail of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum. Cancer TTierapy 67 (5): 493–494Google Scholar
  11. 79.
    Chaplinski T, Lazio J, Moore J, Silverman P (1983) Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma. Cancer Therapy Rep 67 (11): 1009–1012Google Scholar
  12. 80.
    Triozzi PL, Kenney P, Young D, Rinehart JJ (1987) Open label Phase II trial of recombinant beta interferon (IFN-ßser) in patients with colorectal cancer. Cancer Treat Rep 71 (10): 983–984PubMedGoogle Scholar
  13. 81.
    Ullis PK, Brown TD, Beougher K, et al (1987) Phase II trial of recombinant beta interferon in advanced colorectal cancer. Cancer Treat Rep 71 (10): 965–967Google Scholar
  14. 82.
    O’Connel MJ, Moertel CG, Schutt AJ, Sherwin SA (1986) Phase II clinical trial of human recombinant gamma interferon in patients with advanced colorectal cancer (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 27: 181Google Scholar
  15. 83.
    Wadler S, Wiernik PH: 5-fluoruracil and rIFN-a 2: a rationally designed regimen against colorectal carcinoma. Clin Res 36: abstract 803Google Scholar
  16. 84.
    Rios A, Levin B, Ajani J et al (1987) Combination of recombinant human interferon gamma and 5-fluoruracil n the treatment of patients with advanced colorectal carcinoma (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 6: 328Google Scholar
  17. 84a.
    84a.Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985) Antitumor activity of rekombinant-derived IFN-a in metastatic colon carcinoma. J Clin Oncol 3: 1522–28PubMedGoogle Scholar

Ovarialkarzinom

  1. 85.
    Epstein LB, Shen JT, Abelle JS et al (1980) Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semisolid agar technique. Ann NY Acad Sci 350: 228–244PubMedCrossRefGoogle Scholar
  2. 86.
    Gronroos M, Maenpaa J, Soderstorm KO et al (1983) Effects of Alpha and Gamma Interferons and Cytostatics on Ovarian Cancer in the Subrenal Capsule Assay. Med Biol, 61 (5), 275–9PubMedGoogle Scholar
  3. 87.
    Wilson JKV, Bittner G, Borden EC (1984) Antiproliferative activity of human interferons against ovarian cancer cells grown in human tumor stem cell assay. J Interferon Res 4: 441–447CrossRefGoogle Scholar
  4. 88.
    Einhorn N, Cantell K, Einhorn S, Strander H (1982) Human Leukocyte Interferon Therapy for Advanced Ovarian Carcinoma. Am J Clin Oncol 5 (2), 167–172PubMedCrossRefGoogle Scholar
  5. 89.
    Einhorn N, Ling P, Einhorn S, Strander H (1988) A Phase II Study on Escalating Interferon Doses in Advanced Ovarian Carcinoma. Am J Clin Oncol 11 (1), 3–6PubMedCrossRefGoogle Scholar
  6. 90.
    Abdulhay G, DiSaia PJ, Blessing JA, Creasman WT (1985) Human Lymphoblastoid Interferon in the Treatment of Advanced Epithelial Ovarian Malignancies: A Gynecologic Oncology Group Study. Am J Obstet Gynecol 152 (4), 418–423PubMedGoogle Scholar
  7. 91.
    Niloff JM, Knapp RC, Jones G et al (1985) Recombinant Leukocyte Alpha Interferon in Advanced Ovarian Carcinoma. Cancer Treat Rep 69 (7-8), 895–896PubMedGoogle Scholar
  8. 92.
    Freedman RS, Gutterman JU, Wharton JT et al (1983) Leukocyte Interferon (IFN alpha) in Patients with Epithelial Ovarian Carcinoma. J Biol Resp Mod 2 (2), 133–138Google Scholar
  9. 93.
    Berek JS, Hacker NF, Lichtenstein A et al (1985) Intraperitoneal Recombinant Alpha- Interferon for „Salvage“ Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. Cancer Res 45 (9), 4446–53Google Scholar
  10. 94.
    Rambaldi A, Introna M, Colotta F et al (1985) Intraperitoneal Administration of Interferon Beta in Ovarian Cancer Patients. Cancer 56 (2), 294–301PubMedCrossRefGoogle Scholar
  11. 95.
    Welander C, Homesley H, Levin E, Reichs S (1986) Phase II Trial of the Efficacy of Human Recombinant Interferon Gamma ( RIFN GAMMA) in Recurrent Ovarian Adenocarcinomas (meeting abstract ). Proc Am Soc Clin Oncol 5, 221Google Scholar
  12. 96.
    Markman MD, Acquisto R, Hakes T et al (1987) Lack of Efficacy of Rekombinant Gamma Interferon (rGI) Administered by the Intraperitoneal (IP) Route as Therapy of Refractory Ovarian Carcinoma ( ROC ). Clin Res 35, 806AGoogle Scholar

Mammakarzinom

  1. 97.
    Balkwill F, Watling D, Taylor-Papadimitrou J (1978) Inhibition by lymphoblastoid interferon of growth cells derived from the human breast. Int J Cancer 22: 258–265PubMedCrossRefGoogle Scholar
  2. 98.
    Jakesz R, Herjaschki D, Kolb R et al (1981) In vitro inhibitory effect of interferon on DNA-synthesis of breast cancer cells and relationship to steriod receptors. Eur Surg Res 13: 31Google Scholar
  3. 99.
    Balkwill F, Taylor-Papadimitrou J, Fantes VH (1980) Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in a thymic (nude) mice. Eur J Cancer 16: 569–573PubMedCrossRefGoogle Scholar
  4. 100.
    Gutterman J, Blumenschein R, Alexanian R et al (1980) Leukocyte interferon induced tumor regression in human metastatic cancer, multiple myeloma and malignant lymphoma. Am Intern Med 93: 399–406Google Scholar
  5. 101.
    Borden EC, Holland JF, Dao TL et al (1982) Leukocyte-Derived Interferon (Alpha) in Human Breast Carcinoma. The American Cancer Society Phase II Trial. Ann Intern Med 97 (1), 1–6PubMedGoogle Scholar
  6. 102.
    Sherwin SA, Mayer D, Ochs JJ et al (1983) Recombinant Leukocyte a Interferon in Advanced Breast Cancer. Results of a Phase II Efficacy Trial. Ann Intern Med 98 (5), 598–602PubMedGoogle Scholar
  7. 103.
    Silver HKB, Conners J, Salinas FA (1983) Antiviral Res 1: 90Google Scholar
  8. 104.
    Muss HB, Kempf RA, Martino S, et al (1984) A Phase II Study of Recombinant Alpha Interferon in Patients with Recurrent or Metastatic Breast Cancer. J Clin Öncol 2 (9), 1012–6PubMedGoogle Scholar
  9. 105.
    Sikora K, Smedley H (1983) Br Med J 286: 739–740CrossRefGoogle Scholar
  10. 106.
    Goodwin BJ, Brenckman W (1984) Phase II Trial of Human Lymphoblastoid IFN in Metastatic Breast Cancer. Proc Annu Meet Am toe Clin Oncol 3, C-233Google Scholar
  11. 107.
    Sarna GP, Figlin RA (1985) Phase II Trial of Alpha. Lymphoblastoid Interferon Given Weekly as Treatment of Advanced Breast Cancer. Cancer Treat Rep 69 (5), 547–9PubMedGoogle Scholar
  12. 108.
    Nethersell A, Smedley H, Katrak M, et al (1984) Recombinant Interferon in Advanced Breast Cancer. Br J Cancer, 49 (5), 615–20PubMedCrossRefGoogle Scholar
  13. 109.
    Quesada JR, Hawkins M, Horning S, et al (1984) Am J Med 77: 427–432PubMedCrossRefGoogle Scholar
  14. 110.
    Lenzhofer R, Micksche M, Dittrich C et al (1984) Drugs exp Clin Res 7: 463–470Google Scholar
  15. 111.
    Padmanabhan N, Balkwill FR, Bodmer JG et al (1985) Recombinant DNA Human Interferon Alpha 2 in Advanced Breast Cancer: A Phase 2 Trial. Br J Cancer 51 (1), 55–60PubMedCrossRefGoogle Scholar
  16. 112.
    Bruntsch U, Groos G, Tigges FJ et al (1984) Leck of response on 9 patients with breast cancer treated with fibroblast interferon. Cancer Chemother Pharmacol 13: 39–42PubMedCrossRefGoogle Scholar
  17. 113.
    Quesada JR et al (1982) Clinical and Immunological Study of ß-IFN by Intranmuscular Route in Patients with Metastatic Breast Cancer. J Interferon Res 2, 593–99PubMedCrossRefGoogle Scholar
  18. 114.
    Van der Burg M et al (1985) Recombinant IFN-Gamma (Immuneron): Results of a Phase I Trial in Patients with Cancer. J Biol Response Mod 4, 264–272PubMedGoogle Scholar
  19. 115.
    Ikic D, Maricic Z, Oresic W et al (1981) Application of Human Leucocyte Interferon in Patients with Urinary Bladder Papillomatosis, Breast Cancer, and Melanoma. Lancet 1: 1022–1024Google Scholar
  20. 116.
    Szepesi S, Jacobi V, Rübesam D: Intraläsionale Behandlung assärer Mammakarzinom Metastasen mit fiblaferon: Prüfung der antitumoralen Wirkung und erste klinische Erfahrungen. 2. Laupheimer SymposiumGoogle Scholar
  21. 117.
    Pouillart P, Palangie T, Jouvre M, Garcia-Giralt E, Fridman WH, Magdalenart H, Falcoff E, Billiau A (1982) Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastatis and on hormone receptors. Eur J Cancer Clin Oncol 18 (10): 929–935PubMedCrossRefGoogle Scholar
  22. 118.
    Dimitrou NV, Meyer CJ, Strander H, Einhorn S, Cantell K (1984) Interferons as a Modifier of Estrogen receptors. Ann Clin Lab Science, Vol 14. 1, p. 32–38Google Scholar
  23. 119.
    Fentiman S, Balkwill FR, Cuzick J, et al (1987) A Trial of Human Alpha Interferon as an Adjuvant Agent in Breast Cancer after Loco-Regional Recurrence. Eur J Surg Oncol 13 (5), 425–8PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • P. von Wussow

There are no affiliations available

Personalised recommendations